Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.
A new technology for cellular immunotherapy developed by Abramson Cancer Center researchers at Penn Medicine showed promising anti-tumor activity in the lab against hard-to-treat cancers driven by the once-considered “undruggable” KRAS mutation, including lung, colorectal, and pancreatic.
Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer.
MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird’s VISTA antagonist antibody, as a novel immunotherapy for cancer.
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment.
SEATTLE — July 7, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
Two Roswell Park Comprehensive Cancer Center experts were invited to present new insights on treatment of gastroesophageal cancers during the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021. In their talks, both presented July 1, the Roswell Park physician-researchers highlighted easily adoptable methods that may help other clinicians to provide care supporting improved patient outcomes.
Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumours.
Many people don’t realize that the trillions of bacteria, viruses, and fungi residing within the gastrointestinal tract––collectively called the gut microbiome–– are connected to overall health, and specifically to cancer.
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
DALLAS – June 14, 2021 – Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system’s cancer-killing CD8+ T cells.
Reported in the current issue of Cancer Cell and led by Ludwig investigators Taha Merghoub and Jedd Wolchok at Memorial Sloan Kettering (MSK) and Charles Rudin of MSK, the study shows that cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), a molecule that they surprisingly found on the surface of highly activated, cytotoxic and proliferative CD8+ T-cells.
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month this June.
A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy.
Led by Ludwig Lausanne’s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how an immune factor known as interleukin-10 orchestrates the functional revival of “terminally exhausted” tumor-infiltrating T lymphocytes (TILs), which have so far proved impervious to stimulation by immunotherapies. It also demonstrates that the factor, when applied in combination with cell therapies, can eliminate tumors in mouse models of melanoma and colon cancer. The findings are reported in the current issue of Nature Immunology.
Hanna and Mark Gleiberman give $12 Million to UC San Diego to support the internationally recognized head and neck cancer center at UC San Diego Health. Funding will support research and patient experience.
SEATTLE — May 4, 2021 — Below are summaries of recent Fred Hutch research findings and other news.If you are covering news at the upcoming American Society of Gene & Cell Therapy, American Society of Clinical Oncology, or other conferences, feel free to reach out to our media team for help sourcing experts: [email protected]
The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia.
Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor, CAR, T cell therapy and more.
Researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have designed a completely novel potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body’s own immune system to destroy it.
A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
With summer approaching and more and more people getting vaccinated for COVID-19, many San Diegans eagerly anticipate the season best known for outdoor activities. But with more time in the sun comes the need for sun-safe practices. During the pandemic,…
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Medical researchers from Case Western Reserve University, New York University (NYU), and University Hospitals have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply artificial intelligence (AI) tools for predicting which lung cancer patients will respond to immunotherapy.
MD Anderson and TriSalus announced a strategic research collaboration to evaluate the treatment of liver and pancreas tumors with the investigational therapy SD-101 in combination with immunotherapy using a novel delivery approach.
Researchers at the Bloomberg Kimmel Institute for Caner Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. T-cell receptors are found on the surface of immune T cells. These receptors bind to certain antigens, or proteins, found on abnormal cells, such as cancer cells and cells infected with a virus or bacteria, to guide the T cells to attack and destroy the affected cells.
A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule.
The University of Kansas Cancer Center is the first and only site in the region to offer CAR T-cell therapy to treat multiple myeloma, a type of blood cancer that affects about 30,000 people each year.
Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount Sinai study published in Nature in March. NASH affects as many as 40 million people worldwide and is associated with obesity and diabetes.
The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other malignancies, according to lead author Fumito Ito, MD, PhD, FACS.
In a new article published in Cancer Immunology Research, the Moffitt team shows that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models and may be a potential treatment option for patients with advanced melanoma.
Creating “super soldiers” of specific white blood cells to boost an anti-tumour response has been shown in a series of elegant experiments by Princess Margaret researchers.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine.
International cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, has been named a 2021 Dan David Prize Laureate.
A paper published today in Nature shows how chemicals in the areas surrounding tumors – known as the tumor microenvironment – subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
A new study led by Washington University School of Medicine in St. Louis has revealed a detailed map of the genes, proteins, infiltrating cells and signaling pathways that play key roles in driving glioblastoma. The study, of 99 tumors from patients, is the largest and most detailed schematic of this deadly brain tumor.
DALLAS – Feb. 8, 2021 – A new nanoparticle-based drug can boost the body’s innate immune system and make it more effective at fighting off tumors, researchers at UT Southwestern have shown. Their study, published in Nature Biomedical Engineering, is the first to successfully target the immune molecule STING with nanoparticles about one millionth the size of a soccer ball that can switch on/off immune activity in response to their physiological environment.
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
A phase II clinical trial shows that changing the gut microbiome through fecal transplant can transform cancer patients who never responded to immunotherapy into patients who do.
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won’t respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.
Researchers uncovered how stanniocalcin-1, or STC1, works inside a tumor cell to block a cellular “eat-me” signal that typically triggers the immune system to produce T cells to fight the tumor. The findings provide a potential target to improve immune responses to cancer.
Researchers at Canada’s McMaster University have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer.
MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer. The collaboration will work through MD Anderson’s immunotherapy platform to design pre-clinical and clinical studies.